多组分干预延缓CKD G3-G4进展的系统综述与Meta分析
该系统综述与Meta分析纳入19项随机对照试验共36,296例CKD G3-G4患者,评估多组分干预(MCI)延缓CKD进展的效果,中位随访24个月。结果显示MCI对eGFR、eGFR斜率及HbA1c有小幅改善,但对白蛋白尿、血压及不良事件无显著影响,证据确定性为低至中等。
要点
- MCI可小幅改善CKD G3-G4患者的eGFR和eGFR斜率,但临床相关性有限。
- MCI对HbA1c有中等程度降低,对白蛋白尿、血压及不良事件无显著影响。
- 医生主导的团队照护可能优于非医生主导,但获益的临床相关性 modest。
核心结论
- MCI可能延缓CKD G3-G4进展并改善血糖控制,但eGFR和HbA1c证据确定性低,eGFR斜率证据确定性中等,总体临床相关性有限。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Cochrane CENTRAL、Web of Science及CINAHL至2025年7月30日。
- 纳入19项随机对照试验,共36,296例CKD G3-G4患者,干预至少持续6个月,中位随访24个月。
- 采用随机效应Meta分析评估MCI对主要结局eGFR及次要结局的效果。
主要发现
- 与对照相比,MCI使eGFR平均差异为1.18 ml/min per 1.73 m²(95%CI 0.09至2.27;19项试验;低确定性证据)。
- MCI使eGFR斜率平均差异为0.61 ml/min per 1.73 m²/yr(95%CI 0.16至1.06;6项试验;中等确定性证据)。
- MCI使HbA1c平均差异为-0.26(95%CI -0.49至-0.02;9项试验;低确定性证据)。
- 对白蛋白尿、血压或不良事件未观察到统计学显著效应。
关键数值与推荐
- MCI组成部分包括行为改变、指南导向药物治疗、赋能技术及团队照护的混合。
- 医生主导的团队照护似乎优于非医生主导的团队照护,但获益的临床相关性有限。
临床怎么用
- 对于CKD G3-G4患者,可考虑采用多组分干预以小幅延缓肾功能下降并改善血糖控制。
- 干预设计可整合行为改变、指南导向药物治疗、赋能技术及团队照护,但需注意证据确定性有限。
局限性
- eGFR和HbA1c结局的证据确定性低,eGFR斜率证据确定性中等,总体临床相关性有限。
- 需要高质量研究确认MCI在该高危人群中的有效性、成本效益及可扩展性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Multicomponent interventions with two or more intervention strategies are increasingly used to manage patients with CKD G3-G4. Existing multicomponent interventions had a modest effect on slowing CKD progression, although the certainty of evidence was low for eGFR and moderate for eGFR slope. Among multicomponent interventions, physician-led team-based care seemed superior to non-physician-led team-based care, albeit the clinical relevance of the benefit was modest. BACKGROUND: Various multicomponent interventions (MCIs) have been increasingly used for managing patients with CKD G3-G4, but they have not been systematically evaluated for the collective evidence of their effectiveness. Hence, we conducted this systematic review and meta-analysis to evaluate the effectiveness of MCIs in delaying CKD progression and improving health outcomes in patients with CKD G3-G4. METHODS: We completed a systematic literature search in PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Cumulative Index to Nursing and Allied Health Literature from inception to July 30, 2025. We included randomized controlled trials studying the effectiveness of MCIs lasting at least 6 months among patients with CKD G3-G4. We used random-effects meta-analyses to estimate the effectiveness of MCIs on the primary outcome, eGFR, and secondary outcomes, including other kidney function indicators, CKD risk factors, and adverse events. RESULTS: Nineteen randomized controlled trials (36,296 patients with CKD G3-G4; median follow-up of 24 months) were included. Components of MCI included a mix of behavioral modifications, guideline-directed medical therapy, enabling technology components, and team-based care. Compared with control, MCIs were associated with small improvements in eGFR (mean difference [MD]=1.18 ml/min per 1.73 m 2 ; 95% confidence interval [CI], 0.09 to 2.27; 19 trials, low certainty of evidence), eGFR slope (MD=0.61 ml/min per 1.73 m 2 /yr; 95% CI, 0.16 to 1.06; six trials, moderate certainty of evidence), and a moderate reduction in HbA1c (MD=-0.26; 95% CI, -0.49 to-0.02; nine trials, low certainty of evidence). No statistically significant effects were observed for albuminuria, BP, or adverse events. CONCLUSIONS: Our findings suggest the potential role of MCIs in delaying CKD progression and improving glycemic control among patients with CKD G3-G4. Nonetheless, the certainty of evidence is low for eGFR and HbA1c and moderate for eGFR slope, suggesting overall modest clinical relevance. High-quality studies are needed to confirm the effectiveness, cost-effectiveness, and scalability of MCIs for this high-risk patient group.
引用
- Ma C, Wu L, Li Y, et al. Effectiveness of Multicomponent Interventions in Slowing Progression of CKD Stages G3-G4: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2026. PMID: 41701545. doi:10.2215/CJN.0000000996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。